
    
      This is a randomized controlled, double-blind, multicenter, phase III clinical study to
      compare efficacy and safety of Abivertinib maleate versus first-line standard therapy
      EGFR-TKI for the treatment of patients with advanced non-small cell lung cancer with
      sensitive EGFR mutation
    
  